Medtronic PLC (NYSE:MDT) reported its fiscal fourth quarter 2026 results before the opening bell on Wednesday.
The company posted revenue of $9.81 billion, beating the estimate of $9.62 billion, and EPS of $1.55, in line with the $1.55 estimate, according to Benzinga Pro.
Something went wrong.
Ahead of quarterly earnings, UBS analyst Priya Sachdeva maintained Medtronic with a Neutral rating while lowering the price target from $104 to $90.
The medical device giant's next quarterly cash dividend of 71 cents per share has an anticipated ex-dividend date in late June 2026 and an estimated payment date in July 2026.
